


# The Goal Attainment Scaling Method is Robust to Violations of Normality in Goal Scales: A Simulation Study.

Taylor Dunn<sup>1</sup>, Justin Stanley<sup>1</sup>, Kari Knox<sup>1</sup>, Sanja Stanojevic<sup>1,2</sup>, Susan Howlett<sup>1,2</sup>, Kenneth Rockwood<sup>1,2</sup>

<sup>1</sup>Ardea Outcomes <sup>2</sup>Dalhousie University

## Background

- **Goal attainment scaling (GAS)** is a patient-centric outcome measure that captures meaningful change through personally identified goals of treatment.
- GAS is generally a **three-step process**:



**IDENTIFY GOALS**  
Clinician interviews subject/caregiver to identify goals of treatment (usually 3)


**BUILD GAS SCALES**  
Set 5-point attainment scales for each identified goal

**MEASURE ATTAINMENT**  
Rate during follow-up whether the goals have been attained

- A **key assumption** in the GAS method is that scores on the 5-point scales approximate a **normal distribution**.
- Using data simulation techniques (introduced by Urach et al. 2019), we investigated whether **GAS statistical properties varied** if the assumption of **normality was violated**.


## Results

Normally-distributed scores vs uniformly-distributed scores




**Statistical power does not differ significantly between normally-distributed and uniformly-distributed scores**

Power vs simulated treatment effect for 60 subjects



**Measured effect sizes slightly higher with normally-distributed compared to uniformly-distributed scores**

Simulated vs mean measured effect size for 60 subjects



- **Normally-distributed** scores do not differ appreciably from **uniformly-distributed** scores in terms of **power to detect a treatment effect**.
- **Measured effect size** is slightly higher with **normally-distributed** scores, but only for **large simulated effect sizes**.

## Results (cont.)

Difference in power (**normal** - **uniform**) for all simulation scenarios

Number of subjects	3 goals per subject							4 goals per subject						
	0.3	0.4	0.5	0.6	0.7	0.9	1.1	0.3	0.4	0.5	0.6	0.7	0.9	1.1
80	0.5%	1.4%	1.7%	1.4%	1.2%	0.1%	0.0%	0.8%	1.2%	1.1%	1.2%	0.6%	0.1%	0.0%
70	0.9%	1.2%	1.8%	1.7%	0.9%	0.5%	0.0%	1.1%	1.4%	1.7%	1.5%	0.9%	0.1%	0.0%
60	1.2%	1.1%	2.2%	1.7%	1.6%	0.9%	0.1%	0.6%	1.3%	1.9%	1.9%	1.3%	0.4%	0.0%
50	0.5%	0.9%	1.7%	2.3%	2.2%	1.8%	0.4%	0.6%	1.4%	2.0%	2.3%	2.1%	0.8%	0.2%
40	0.5%	0.6%	2.2%	2.6%	3.5%	2.9%	1.6%	0.7%	1.1%	1.6%	1.9%	2.9%	1.7%	0.8%

Number of subjects	5 goals per subject							6 goals per subject						
	0.3	0.4	0.5	0.6	0.7	0.9	1.1	0.3	0.4	0.5	0.6	0.7	0.9	1.1
80	1.5%	1.4%	1.5%	0.7%	0.2%	0.0%	0.0%	0.6%	1.2%	1.1%	0.7%	0.2%	0.0%	0.0%
70	0.5%	1.2%	2.0%	0.6%	0.9%	0.1%	0.0%	0.8%	1.9%	1.1%	1.0%	0.6%	0.1%	0.0%
60	0.6%	1.4%	1.3%	1.9%	0.8%	0.3%	0.0%	0.7%	0.8%	1.9%	1.2%	0.7%	0.2%	0.0%
50	0.4%	1.5%	1.7%	1.8%	1.6%	0.8%	0.1%	0.7%	1.3%	1.9%	1.8%	1.5%	0.3%	0.0%
40	0.8%	1.4%	1.7%	1.9%	2.2%	1.5%	0.6%	0.4%	0.6%	1.2%	1.6%	2.3%	1.1%	0.4%

- For the most part, there is less than a 2% difference in power to detect a treatment effect.

## Methods

- We employed a latent variable model (Urach et al. 2019) to generate GAS data.
- The following parameters were varied: number of subjects, treatment effect size, and number of goals per subject.
- Latent goal scores were discretized into 5-point scales following **uniform** and **normal** distributions.
- 10,000 trials were simulated for each set of parameters.
- Two-sided *t*-tests on GAS T-scores were used to test the null hypothesis of no treatment effect.
- Power was the percentage of simulations detecting a significant effect at  $\alpha = 0.05$ . Standardized effect sizes were computed as Cohen's *d*.